Xenon Pharmaceuticals had its Relative Strength (RS) Rating upgraded from 66 to 74 Friday — a welcome improvement, but still below the 80 or better score you look for.
How To Invest In Stocks In Both Bull And Bear Markets
This exclusive rating from Investor's Business Daily identifies market leadership with a 1 (worst) to 99 (best) score. The score shows how a stock's price performance over the last 52 weeks holds up against all the other stocks in our database.
History reveals that the market's biggest winners tend to have an RS Rating of above 80 as they launch their largest climbs. See if Xenon Pharmaceuticals can continue to show renewed price strength and hit that benchmark.
While now is not an ideal time to jump in, see if the stock manages to establish and enter a buy zone in heavy trade.
Xenon Pharmaceuticals showed 0% earnings growth in the latest quarterly report. Revenue rose -100%. The company is expected to report its latest results on or around Nov. 5.
The company earns the No. 316 rank among its peers in the Medical-Biomed/Biotech industry group. Aurinia Pharmaceuticals, Incyte and argenx ADR are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Stocks With Rising Relative Strength Ratings
